Table S1. Full Search Strategy

Database	Search
AMED, CINHAL (via	S1 (MH "Multiple Sclerosis")
EBSCO)	S2 "multiple sclerosis"
	S3 "MS"
	S4 "demyelinat*"
	S5 S1 OR S2 OR S3 OR S4
	S6 (MH "Dancing+")
	S7 (MH "Dance Therapy")
	S8 "danc*"
	S9 "ballet"
	S10 "ballroom"
	S11 "tango"
	S12 "jazz"
	S13 "Zumba"
	S14 "movement to music"
	S15 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
	S16 S5 AND S15
	Expanders: Apply equivalent subjects
	\rightarrow AMED: 10
	\rightarrow CINHAL: 60
Medline (via Ovid)	S1 Multiple Sclerosis/
Wiedinie (Via Ovia)	S2 multiple sclerosis.mp.
	S3 MS.mp.
	S4 demyelinat*.mp.
	S5 S1 OR S2 OR S3 OR S4
	S6 exp Dancing/
	So exp Dance Therapy/
	St exp Dance Therapy

	 S8 danc*.mp. S8 ballet.mp. S10 ballroom.mp. S11 tango.mp. S12 jazz.mp. S13 zumba.mp. S14 movement to music.mp. S15 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 S16 S5 AND S15 → 91
Web of Science (Core Collection)	<pre>(TS=("multiple sclerosis" OR "MS" OR "demyelinat*")) AND TS=((danc* OR "ballet" OR "ballroom" OR "tango" OR "jazz" OR "Zumba" OR "movement to music")) → 216</pre>
ProQuest (Health & Medical Collection, Nursing & Allied Health Database, and PsycINFO)	 S1 (noft("multiple sclerosis") OR TI,AB("MS") OR noft("demyelinat*")) S2 (noft(danc*) OR noft("ballet") OR noft("ballroom") OR noft("tango") OR noft("jazz") OR noft("zumba") OR noft("movement to music")) S3 S1 AND S2 → Health & Medical Collection: 173 → Nursing & Allied Health Database: 84 → PsychINFO: 50
Scopus	(TITLE-ABS-KEY ("multiple sclerosis" OR "demyelinat*")) AND (TITLE-ABS-KEY (danc* OR "ballet" OR "ballroom"

 OR "tango" OR "jazz" OR "zumba" OR "movement to music")) → 50	

Table S2. Complete Characteristics of Included Studies

Author, Date,	Sample Characteristics	Intervention	Outcome Measures	Main Findings	Quality
Design	(size ^a , sex, age, MS type,	Characteristics			
	disability status, disease	(type, delivery mode,			
	duration)	dosage, frequency,			
		duration, adverse events,			
		adherence, dropouts)			
Randomized Con	trolled Trial				
Young et al, ³⁵	81 (self-reported	Movement-to-music	Primary:	Primary:	Moderate
2019;	diagnosis);	(M2M, n = 27);	Mobility (TUG)	TUG	(60%
proof-of-concept				Pre M2M group: 12.3 ± 12.4	quality
trial	66F/15M;	Group, in-person;	Walking endurance (6MWT)	Post M2M group: 12.2 ± 14.1	criteria met)
	Mean age dance group,	60 minutes x 3/week for		Group difference $(P = .03)^*$	
	49.67 ± 9.40 years;	12 weeks;	Lower-extremity		
		,	functional strength	Post hoc, between M2M-WC	
	MS type, NR;	AE (study-related), 1;	(5XSTS)	$(P = .01)^*$	
				Cohen's $d = 0.7$, medium ES	
	PDDS range, 0-6 (no	Adherence, 53.7%	Secondary:		
	disability - bilateral		Fatigue and pain	Post hoc, between AY-WC	
	support);	Lost to follow-up, $n = 3$	(PROMIS Fatigue and	$(P = .09)^{\circ}$	
		_	Pain Interference Short		
	Mean disease duration of	Adapted yoga (AY, n =	Forms 8a)	<u>6MWT</u>	
	dance group, 13.56 ± 8.26	26);		Pre M2M group: 341.7 ± 110.1	
	years			Post M2M group: $383.9 \pm$	
		Group, in-person;		134.1	
		60 minutes x 3/week for 12 weeks;		Group difference accounting for PDDS $(P = .04)^*$	
		AE (study-related), 0;		Post hoc, between M2M-WC $(P = .04)^*$	

		Adherence, 67.7%		Cohen's $d = 0.6$, medium ES	
		Lost to follow-up, $n = 5$		Post-hoc, between AY-WC $(P = .25)$	
		Waitlist control (WC, n = 28);		$\frac{5XSTS}{\text{Group difference } (P = .41)}$	
		Biweekly, educational newsletters;		Secondary:	
		Lost to follow-up, $n = 5$		PROMIS-FatigueGroup difference accountingfor PDDS $(P = .08)^{\circ}$	
				Post hoc, between M2M-WC $(P = .09)^{\circ}$ Cohen's $d = 0.49$, medium ES	
				$\frac{PROMIS-Pain}{Group difference} (P = .70)$	
Nonrandomized	Studies				
Mandelbaum et al, ³⁸ 2016;	8 (confirmed diagnosis);	Salsa dance;	Gait (T25-FW, MSWS- 12)	<i>Pre-post, within group</i> $\underline{TUG}(P = .02)^*$	Moderate (60%
uncontrolled, before-and-after	5F/3M;	Group, in-person;	Balance (DGI, BBS)	Pre: 9.5 (8.6; 10.0) Post: 8.5 (8.1; 8.9)	quality criteria met)
study	Age range, 29-63 years;	60 minutes x 2/week for 4 weeks;	Mobility (TUG)	$\frac{\text{GLTEQ}}{\text{Total minutes/model}} (P = .01)^*$	
	7 RRMS/1 SPMS; PDDS range, 0-3 (no	AE, 0;	Balance confidence (ABC)	Total minutes/week Pre: 250.0 (25.0; 447.5) Post: 450.0 (305.0; 731.3)	
	disability-walking disability);	Adherence, 98%	(ABC) Self-efficacy (MSSS)	Moderate exercise (min)	
	<i>,,,,</i>	Dropouts, 0	, ()	Pre: 70.0 (0.0; 338.8)	

D	Disease duration range, 1-	Motivation for PA	Post: 325.0 (240.0; 492.5)
	2 years	(MPAM-R)	
	5	< , ,	Total leisure activity (METs)
		Physical activity	Pre: 28.0 (4.5; 50.8)
		(GLTEQ)	Post: 43.0 (30.0; 67.5)
		MS symptom checklist	$\underline{MS \ Symptoms} \ (P = .05)*$
		(MS Symptoms)	Pre: 5.0 (2.0; 6.8)
			Post: 5.5 (2.3; 8.5)
		Neurological disability	
		(PDDS)	$\underline{\text{DGI}}(P = .09)^{\circ}$
			$ABC (P = .09)^{\circ}$
			$\underline{ADC}(I = .09)$
			T25-FW, MSWS-12, BBS,
			MSSS, PDDS, MPAM-R,
			$\overline{(P > 0.1)}$
			Pre 3-month follow-up
			$\underline{\text{DGI}}(P = .04)*$
			Pre: 22.5 (20.3; 23.8)
			3-month: 24.0 (22.3; 24.0)
			TLIC (D - 05)*
			$\frac{\text{TUG}(P = .05)^{*}}{\text{Pre: }9.5 (8.6; 10.0)}$
			3-month: 8.3 (8.0; 8.9)
			5 monut. 0.5 (0.0, 0.7)
			<u>MSWS-12</u> $(P = .05)^*$
			Pre: 29.2 (1.0; 59.9)
			3-month: 17.7 (1.6; 41.7)
			$\underline{\text{GLTEQ}} (P = .07)^{\circ}$

				T25-FW, ABC, BBS, MSSS, MS Symptoms, MPAM-R, PDDS $(P > .1)$ Pre 6-month follow-up All outcomes $(P > .1)$	
Scheidler et al, ³⁹ 2018; uncontrolled, before-and-after study	8 (confirmed diagnosis); 8F/0M; Age range, 36-65 years; All RRMS; EDSS range, 2.5-6.5 (mild disability-moderate disability); Disease duration, NR	Targeted ballet;Group, in-person;60 minutes x 2/week for16 weeks;AE, 0;Adherence, presetcriteria of over 94% ofclassesDropouts, 2	Ataxia (ICARS and smoothness of movement in 5-meter walk from motion capture data [Uni- Lateral S-index]) Balance (MBT and center of pressure measurements of balance in step-to-stand task [GBM])	Pre-post, within group ICARS Pre: 19.6 ± 6.3 Post: 8.19 ± 6.6 $(P < .001)^*$ Cohen's $d = 2.6$, huge ES <u>Unilateral S-index, right</u> Pre: -81.7 ± 10.9 Post: -75 ± 8.7 $(P = .028)^*$ Cohen's $d = 0.87$, large ES <u>Unilateral S-index, left</u> Pre: -78.6 ± 10.3 Post: -73.2 ± 7.5 $(P = .027)^*$ Cohen's $d = 0.87$, large ES <u>MBT</u> Pre: 16.6 ± 5.0 Post: 23.6 ± 2.6 $(P = .001)^*$ Cohen's $d = 1.2$, very large ES	Moderate- high (80% quality criteria met)
				<u>GBM, back direction</u>	

				$\mathbf{D}_{\mathrm{max}} = 1 \cdot 0$	
				Pre: -4.82 ± 6.9	
				Post: -17 ± 10.4	
				(P = .025)*	
				Cohen's $d = .68$, medium ES	
				GBM, right, left, and front	
				(P > .05)	
				()	
Ng et al, ³⁷ 2020;	13 (confirmed diagnosis);	Ballroom dance (n =	HR-QoL (PROMIS-	Within group, dance group:	Moderate-
controlled,		7);	GH)	$\underline{PROMIS-GH}(P = .03)^*$	high (80%
before-and-after	12F/1M;	');		1100000000000000000000000000000000000	quality
study	121/11/1,	Group, in-person;	Self-efficacy (MSSE)	Post: 42 (34,48)	criteria met)
study	Age range, 40-59 years;	Group, in-person,	Self-efficacy (WISSE)	1 031. 42 (34,40)	enterna met)
	Age range, 40-59 years,	60 minutes x 2/week for	MS Exercise Self-	<u>MSFC ($P = .03$)*</u>	
	12 RRMS/1 PPMS;				
	12 KRIVIS/1 PPIVIS;	6 weeks;	efficacy	Pre: 0.25 (-1.33, 0.35)	
				Post: 0.47 (-0.90, 0.55)	
	PDDS range, 1-4 (mild	AE, 0;	Fatigue (FIS)		
	disability-cane use);			$\underline{PASAT}(P = .03)*$	
		Adherence, all complete	Depression (BDI)	Pre: 49 (31, 55)	
	Disease duration, NR	at least 75% sessions		Post: 55 (45, 60)	
		(preset criteria)	Balance (BBS, DGI)		
				$\underline{FIS}(P=.07)^{\circ}$	
		Dropouts, 0	Mobility (TUG)		
				$\underline{BDI}(P=.07)^{\circ}$	
		No-dance control group	Physical function		
		(n = 6)	(MSFC: 9-HPT, T25-	BBS $(P = .07)^{\circ}$	
			FW, PASAT)		
			,,	<u>TUG</u> $(P = .08)^{\circ}$	
			Exercise intensity (HR,	(())	
			RPE)	<u>MSSE-Control</u> ($P = .46$),	
				$\frac{\text{MSSE-Control}}{\text{MSSE-Function}} (P = .18), \text{MS}$	
				Exercise Self-efficacy $(P = $	
				Exercise Sen-enicacy (P -	

2020; controlled, pilot, before-and-after16F/1M;participatory dance (n = 7);Fatigue (MFIS, FSS, DWI, CFI)Primary: MFIS $(P = .03)^*$ Pre: 43 (19; 48)(60% quality criteria rstudyAge range, 29-65 years; MS Type, NR;Group, in-person; 90 minutes x 2/week for 10 weeks;Secondary: Physical capacity (6MWT, T25-FW, ABC, DGI, 5TSTS, MSWS-12, 9HPT)Primary: MFIS $(P = .03)^*$ Post: 26 (6; 49)(60% quality criteria r2020; controlled, pilot, before-and-after studyMS Type, NR; Post: 26 (6; 49)90 minutes x 2/week for 10 weeks;Secondary: Physical capacity MSWS-12, 9HPT)Primary: Pre: 19 (8; 24)(60% quality pre: 19 (8; 24)Disability status, cane (n = 1), walker (n = 2), crutch (n = 1);AE, NR; Adherence, NR;Sensory function (EmNSA)FSS (P = .31), DWI (P = .87), CFI (P = .25)FSS (P = .31), DWI (P = .87), CFI (P = .25)					.21), <u>DGI</u> ($P = .11$), <u>9HPT</u> ($P = .35$), <u>T25-FW</u> ($P = .53$) Within group, control group: All outcomes ($P > .1$) Between dance & control groups: <u>PROMIS-GH</u> ($P \le .05$)* <u>MSFC</u> ($P \le .05$)* <u>PASAT</u> ($P \le .05$)*	
controlled, pilot, before-and-after study16F/1M; Age range, 29-65 years; MS Type, NR; $= 7$;DWI, CFI)MFIS $(P = .03)^*$ Pre: 43 (19; 48) Post: 26 (6; 49)quality criteria rMS Type, NR; Disability status, cane (n = 1), walker (n = 2), crutch (n = 1);90 minutes x 2/week for 10 weeks;Secondary: Physical capacity (6MWT, T25-FW, ABC, DGI, 5TSTS, MSWS-12, 9HPT)MFIS physical $(P = .02)^*$ Pre: 19 (8; 24) Post: 13 (3; 20)MFIS physical $(P = .02)^*$ Pre: 19 (8; 24) Post: 13 (3; 20)		17 (confirmed diagnosis);				Moderate
before-and-after studyAge range, 29-65 years; MS Type, NR; Disability status, cane (n = 1), walker (n = 2), crutch (n = 1);Group, in-person; PO minutes x 2/week for 10 weeks;Secondary: Physical capacity (6MWT, T25-FW, ABC, DGI, 5TSTS, MSWS-12, 9HPT)Pre: 43 (19; 48) Post: 26 (6; 49)criteria r Post: 26 (6; 49)MFIS physical (P = .02)* Pre: 19 (8; 24) Post: 13 (3; 20)MFIS physical (P = .02)* Pre: 19 (8; 24) Post: 13 (3; 20)MFIS physical (P = .02)* Pre: 19 (8; 24) Post: 13 (3; 20)	· · · · · · · · · · · · · · · · · · ·				5	
studyAge range, 29-65 years; MS Type, NR;Group, in-person;Secondary: Physical capacity $(6MWT, T25-FW,$ ABC, DGI, 5TSTS, MSWS-12, 9HPT)Post: 26 (6; 49)Disability status, cane (n = 1), walker (n = 2), crutch (n = 1);90 minutes x 2/week for 10 weeks;Secondary: Physical capacity $(6MWT, T25-FW,$ ABC, DGI, 5TSTS, MSWS-12, 9HPT)Post: 26 (6; 49)MFIS physical (P = .02)* Pre: 19 (8; 24) Post: 13 (3; 20)MFIS physical (P = .02)* Pre: 19 (8; 24) Post: 13 (3; 20)Adherence, NR;Sensory function (EmNSA)ESS (P = .31), DWI (P = .87), CFI (P = .25)	· • ·	16F/1M;	= 7);	DWI, CFI)	、	
MS Type, NR;90 minutes x 2/week for 10 weeks;Physical capacity (6MWT, T25-FW, ABC, DGI, 5TSTS, MSWS-12, 9HPT)MFIS physical $(P = .02)^*$ Pre: 19 (8; 24) Post: 13 (3; 20)10 weeks;AE, NR;Adherence, NR;Sensory function (EmNSA)FSS $(P = .31)$, DWI $(P = .87)$, CFI $(P = .25)$		Λ go rongo 20.65 voors:	Group in porson:	Sacandamy		criteria met)
MS Type, NR;90 minutes x 2/week for 10 weeks;(6MWT, T25-FW, ABC, DGI, 5TSTS, MSWS-12, 9HPT)MFIS physical $(P = .02)^*$ Pre: 19 (8; 24) Post: 13 (3; 20)Disability status, cane (n = 1), walker (n = 2), crutch (n = 1);90 minutes x 2/week for 10 weeks;(6MWT, T25-FW, ABC, DGI, 5TSTS, MSWS-12, 9HPT)MFIS physical $(P = .02)^*$ Pre: 19 (8; 24) Post: 13 (3; 20)AE, NR;Sensory function (EmNSA) $\underline{FSS} (P = .31), \underline{DWI} (P = .87),$ $\underline{CFI} (P = .25)$	study	Age lange, 29-05 years,	Oroup, in-person,	5	rost. 20(0, 49)	
Disability status, cane (n = 1), walker (n = 2), crutch (n = 1);10 weeks;ABC, DGI, 5TSTS, MSWS-12, 9HPT)Pre: 19 (8; 24) Post: 13 (3; 20)AE, NR;AE, NR;Sensory function (EmNSA) $FSS (P = .31), DWI (P = .87),$ CFI (P = .25)		MS Type, NR;	90 minutes x 2/week for		MFIS physical $(P = .02)^*$	
1), walker (n = 2), crutch (n = 1);AE, NR; Adherence, NR;Sensory function (EmNSA) $\underline{FSS} (P = .31), \underline{DWI} (P = .87),$ $\underline{CFI} (P = .25)$			10 weeks;			
$(n = 1);$ Sensory function $\underline{FSS}(P = .31), \underline{DWI}(P = .87),$ Adherence, NR; $\underline{CFI}(P = .25)$				MSWS-12, 9HPT)	Post: 13 (3; 20)	
Adherence, NR;(EmNSA) $\overline{CFI}(P = .25)$			AE, NR;			
		(n = 1);	Adharanaa ND.	5		
1000000000000000000000000000000000000		Disease duration range, 3	Autorence, NK;	(EIIINSA)	$\frac{\nabla \Gamma I}{\Gamma} (F23)$	
Disease duration range, 521 yearsDropouts, 1Cognitive capacitySecondary:		8,	Dropouts, 1	Cognitive capacity	Secondary:	
$\begin{array}{c} \text{Substant} \\ \text{(SMDT, PASAT)} \\ \end{array} \\ \begin{array}{c} \text{Substant} \\ SUBstan$		J	· · · · · · · · · · · · · · · · · · ·	U I I		

Control art group (n =	Dual Task Performance	$\underline{ABC} (P = .04)^*$
10);		MOWO 12 (D 046)*
Group, in-person;	HR-QoL (MSIS-29, SF-36)	<u>MSWS-12</u> $(P = .046)*$
Group, in person,		<u>9HPT-dominant</u> ($P = .02$)*
Approximately 90	Leg coordination	
minutes x 2/week for 10 weeks;		$\underline{\text{DT}}$ - Cognitive $(P = .03)^*$
		<u>Leg coordination</u> $(P = .046)*$
AE, NR;		DASAT (D = 0.00)
Adherence, NR		$\underline{PASAT} (P = .068)^{\circ}$
		<u>MSIS-29</u> (<i>P</i> =.063)°
		$DT Cost (P = .063)^{\circ}$
		$\underline{\text{DT Cost}}(F = .005)$
		Within group, art group:
		Primary: <u>MFIS</u> $(P = .005)*$
		$\frac{M113}{Pre: 48 (41; 54)}$
		Post: 42 (28; 47)
		<u>MFIS, physical</u> $(P = .01)*$
		Pre: 25 (20; 30)
		Post: 20 (13; 23)
		<u>FSS</u> ($P = .72$), <u>DWI</u> ($P = .74$),
		$\frac{155}{\text{CFI}} (P = .45)$
		Secondary: <u>SDMT</u> $(P = .04)$ *
		<u>DT - Cognitive</u> $(P = .02)^*$

				$\underline{PASAT} (P = .085)^{\circ}$	
Camacho et al, ⁴⁰ 2021; uncontrolled, before-and-after study	 5 (confirmed diagnosis); 4F/1M; Age range, 38-64 years; All RRMS; EDSS, mean of 3.5 ± 1.5 (mild-moderate disability); Disease duration, NR 	Targeted ballet;Group, in-person;60 minutes x 2/week for12 weeks;AE, 0;Adherence, mean hoursof 21.8 ± 4.65 (presetcriteria of 24 hours)Dropouts, 0	Ataxia (ICARS and smoothness of movement in 5-meter walk from motion capture data [Bilateral S-index]) Balance (MBT)	Pre-post, within group:ICARS $(P = .01)^*$ Hedge's $g = -1.21$, large ESMBT $(P = .015)^*$ Hedge's $g = 1.08$, large ESBilateral S-index $(P = .0499)^*$ Hedge's $g = .69$, medium ES	Moderate (60% quality criteria met)
Quantitative Des	criptive Studies	I	I		
Salgado and de Paula Vasconcelos, ⁴³ 2010; case report	 1 (confirmed diagnosis); Female; Age, 45 years; RRMS; EDSS, 3 (moderate disability); Disease duration, 10 years 	Dance/movement therapy; 1 on 1, in-person; 100 minutes x 2/ week for 20 weeks; AE, NR; Adherence and dropouts, N/A	Neurological disability (EDSS, MRD, NRS)	Pre-post changes EDSS Pre: 3 Post: 2 (-1) <u>MRD</u> Pre: 6 Post: 5 (-1) <u>NRS</u> Pre: 64 Post: 71 (+7)	Low (40% quality criteria met)

Charlton et al, ⁴² 2010; evaluation	 11 (confirmed diagnosis); 11F/0M; Age range, 32-70 years; MS type, NR; Disability status, ambulatory without assistance (n = 7), use walkers (n = 4); 	Jazzercise; Group, in-person; 45 minutes x 2/ week for 16 weeks; AE, 0; Adherence, 67-75% Dropouts, n = 3	Questionnaire evaluating participant- reported changes in balance, confidence, coordination, energy, flexibility, mood, and strength	Percentage agreed or strongly agreed outcome improved postintervention: 56% balance and coordination 67% strength and flexibility 78% confidence 100% energy & mood 100% enjoyment & satisfaction with classes & motivation to continue with classes	Low (40% quality criteria met)
Lachance et al, ⁴¹ 2021; single-case experimental study	Disease duration, NR 1 (confirmed diagnosis); +6 other people with reduced mobility Female; Age, 60 years; MS Type, NR; Disability status, walks with a limp; Disease duration, NR	Clinical dance therapy; Group, in-person; 90 minutes x 2/ week for 12 weeks; AE, NR; Adherence, 71% Dropouts, N/A	Primary: Mobility (FSST) Secondary: Mobility (MDRT- behind, MBT)	Tau-U analysis Primary: <u>FSST</u> (P = .86) Tau-U: 0.08 Secondary: <u>MDRT-behind</u> $(P = .034)^*$ Tau-U: -1, Very large ES <u>MBT</u> $(P = .034)^*$ Tau-U: 1, Very large ES	Moderate (60% quality criteria met)

Ares-Benítez et	1 (confirmed diagnosis);	Spanish dance &	Spasticity (MAS)	Pre-post changes	Low (40%
al, ⁴⁴ 2021;		physiotherapy;		BBS	quality
case report	Female;		Balance (BBS)	Pre: 30	criteria met)
		1 on 1, in-person;		Post: 55 (+25 points)	
	Age, 49 years;		Walking endurance		
		60 minutes x 5/week for	(6MWT)	<u>6MWT</u>	
	RRMS;	3 weeks;		Pre: 427.24 m and 1.19 m/s	
			Spatiotemporal gait	Post: 465 m and 1.46 m/s	
	EDSS, 5 (moderate disability);	AE, NR;	patterns (Gaitrite)	(+37.76 m and +0.27 m/s)	
	• / •	Adherence & dropouts,	Muscle strength	MMT	
	Disease duration, 24 years	N/A	(MMT)	Ankle dorsiflexors, +2 points Ankle plantar flexors, +1 point	
			Range of motion	Knee and hip muscles, no	
			(goniometry)	change	
			(gomomeny)	change	
				MAS	
				Sural triceps, -1 point	
				Quadriceps, hamstrings, psoas	
				& adductors, no change	
				, 6	
				Spatiotemporal gait	
				parameters, left lower limb,	
				right lower limb	
				Stride time (s), -0.04, -0.02	
				Step length (cm), +12.6, +13.6	
				Stride length (cm),+26.4,+26.1	
				Base of support (cm),+3.9,+2.8	
				Single support (%GC), +5.2,	
				+3.3	
				Double support (%GC), -10.2,	
				-9.8	
				Balance (%GC), +3.3, +5.4	

				Speed (cm/s), +24.8 Cadence (steps/minute), +4.6	
Mixed Methods S	Studies				
Mason, ⁴⁵ 2020; thesis	5 (self-reported diagnosis); Sex, age, MS type, disability status, and disease duration, NR	Participatory dance; Group, in-person; 75 minutes x 1/week for 6 weeks; AE, NR; Adherence, 93% Dropouts, n = 0	<i>Quantitative</i> Self-efficacy (MSSE- 10) <i>Qualitative</i> Exit questionnaire	QuantitativePre-post, within group $\underline{MSSE-10}$ Pre: 880Post: 906 $(P = .225)$ QualitativeParticipants reportedexperiencing improvements inself-efficacy, self-confidence& physical well-being.	Low (20% quality criteria met)
Whiteside and Ruckert, ⁴⁶ 2020; evaluation	 22 (self-reported diagnosis) including n = 12 (AM group) and n =10 (PM group) 21F/1M; Age, NR; MS type, NR; Disability status, multiple walking aids, wheelchairs (n = 2); Disease duration, NR 	Participatory dance; Group, in-person; 75 minutes x 1/week for 10 weeks; AE, NR; Adherence & dropouts, N/A (drop-in format)	QuantitativeFatigue (FSS)Balance confidence(ABC)Gait (MSWS-12)QualitativeInterviews &participant observation	Quantitative Pre-post, within group ABC AM group $(P > .05)$ PM group $(P = .07)^{\circ}$ $\frac{FSS}{AM}$ group $(P = .02)^{*}$ Pre: 5.4 Post: 4.7PM group $(P = .06)^{\circ}$ $\frac{MSWS-12}{AM}$ group $(P = .06)^{\circ}$	Moderate (60% quality criteria met)

Qualitative Study	V			PM group $(P > .05)$ <i>Qualitative</i> Participants reported experiencing improvements in body confidence & awareness, well-being, belonging & quality of life.	
Baeza and Fuertes, ⁴⁷ 2022	 1 (confirmed diagnosis); Female; Age, 53 years; MS type, NR; Disability status, carries out daily activities independently using a cane at home and wheelchair outside; Disease duration, 18 years 	Creative movement practice; Solo, remote; 100 minutes x 1/week for 6 weeks; AE, NR; Adherence & dropouts, N/A	Interviews using visual narratives from photographs as metaphors	Participant reported improvements in body confidence & awareness, emotional confidence & well- being & connectedness with family members.	Low (40% quality criteria met)

5STS, Five Times Sit-to-Stand; 6MWT, 6-Minute Walk Test; 9HPT, 9-Hole Peg Test; ABC, Activities-Specific Balance Confidence Scale; AE, adverse events; BBS, Berg Balance Scale; BDI, Beck Depression Inventory; CFI, Cognitive Fatigability Index; DGI, Dynamic Gait Index; DT, dual task; DWI, Distance Walked Index; EDSS, Expanded Disability Status Scal;, EmNSA, Erasmus modified Nottingham Sensory Assessment; ES, effect size; F, female; FIS, Fatigue Impact Scale; FSS, Fatigue Severity Scale; FSST, Four Square Step Test; GC, gait cycle; GLTEQ, Godin Leisure Time Exercise Questionnaire; HR, heart rate; HR-QoL, health-related quality of life; ICARS, International Cooperative Ataxia Rating Scale; M, male; MAS, Modified Ashworth Scale);MBT, Mini-Balance Evaluation Systems Test; MDRT, Multi-Directional Reach Test; MFIS, Modified Fatigue Impact Scale; MMT, Daniels-Worthingham Manual Muscle Test; MPAM-R, Motives for Physical Activity Measure-Revised; MRD, Minimal Record Disability; MSFC, MS Functional Composite Score; MSIS-29, MS Impact Scale-29; MSSE, Multiple Sclerosis Self-efficacy Scale; MSSS, MS Self-Efficacy Scale; MSWS-12, 12-Item Multiple Sclerosis Walking Scale; N/A, not applicable; NR, not reported; NRS, Scripps Neurologic Rating Scale; PASAT, Paced Auditory Serial Addition Test; PDDS, Patient Determined Disease Steps scale; PPMS, primary progressive MS; PROMIS-GH, Patient-Reported Outcomes Measurement Information System Global Health; RPE, rating of perceived exertion; RRMS, relapsing-remitting MS; T25-FW, Timed 25-Foot Walk Test; TUG, Timed Up and Go; SF-36, Short Form Health Survey; SDMT, Symbol Digit Modalities Test; SPMS, secondary progressive MS.

^aAll people with MS unless otherwise specified. * $P \le .05$ °trend towards significance (P < .1)

Table S3. Examples of Qualitative Data

Themes	Sample Qualitative Data
Theme 1: Body awareness and physical confidence	 "When I fell, again in the same place during the week, this time instead of battering and bruising and injuring myself, I kept on my feet because I automatically did that backward, straight leg, and it kept me on my feet. It then let me reach forward and hold onto the sink, so I could get my balance back."⁴⁶ "I have noticed that I am more confident in trying things that I thought I couldn't do, or that I knew I would end up exhausted after, like running or stretching."⁴⁵
Theme 2: Psychological well- being	"I enjoy the class. Sometimes I end the class feeling tired but in a better and more energetic mood. In those days where I felt tired even before starting the class, I knew that I would not be forced to do more than I was able to." ⁴⁵
Theme 3: Sense of belonging	"You're going somewhere where you don't have to explain as much. Because I don't mind going in and saying 'this is what my symptoms are; this is what I find difficult; this is what I want to get out of it,' but it's more just that when I'm saying that, I don't then have to explain what that actually means on top of having to have that initial explanation." ⁴⁶ "The class is a totally nonjudgmental atmosphere, so self- conscious inhibition is minimal." ⁴⁵
Theme 4: Social relationships	"When you feel the heat and it is heat that comes into your bodyyou're smiling; you're feeling warmer. And I think when you see each other and we're passing and you're smiling, I love

that part when you're just doing the dancing with each other and that's lovely." ⁴⁶
"This image reflects union, and it is what I have felt with my daughter in the last activity of embracing slowly. It is something we never do and should being such a simple and good gesture, we should do it more often." ⁴⁷ (translated from Spanish to English)

Studies	Qua	litativ	e studi	ies		Randomized controlled trials					Non	rando	mized	studie	es	Qua stud		ve des	scripti	ve	Mixed-methods studies						MMAT score	Overall quality
Author, Date, Design	1.1	1.2	1.3	1.4	1.5	2.1		2.3	2.4	2.5	3.1	3.2	3.3	3.4	3.5	4.1	4.2	4.3	4.4	4.5	5.1	5.2	2 5.	.3	5.4	5.5		
Baeza and Fuertes, ⁴⁷ 2022	Y	Y	CT	N	N																						**	Low
Young et al, ³⁵ 2019; proof-of- concept trial						Y	Y	N	Y	N																	***	Moderate
Mandelbaum et al, ³⁸ 2016; uncontrolled,											Y	Y	CT	N	Y												***	Moderate
before-and-after study																												
Scheidler et al, ³⁹ 2018;											Y	Y	Y	Y	CT												****	Moderate- high
uncontrolled, before-and-after study																												
Ng et al, ³⁷ 2020; controlled, before- and-after study											N	Y	Y	Y	Y												****	Moderate- high
Van Geel et al, ³⁶ 2020; controlled, before-and-after study											Y	Y	Y	N	СТ												***	Moderate
Camacho et al, ⁴⁰ 2021; uncontrolled, before-and-after											СТ	Y	Y	Y	СТ												***	Moderate
study Salgado and de Paula Vasconcelos, ⁴³																СТ	N	Y	Y	СТ							**	Low
2010; case report Charlton et al, ⁴² 2010; survey																N	N	N	Y	Y							**	Low

Table S4. Mixed Methods Appraisal Tool (MMAT) Quality Assessment

Lachance et al, ⁴¹													CT	Y	Y	Ν	Y						***	Moderate
2021; single-case																								
experimental																								
study																								
Ares-Benítez et													CT	Ν	Y	Y	Ν						**	Low
al, ⁴⁴ 2021; case																								
report																								
Mason, ⁴⁵ 2020;	CT	CT	Y	Y	Y			CT	Y	Y	Y	Y						Y	Ν	Ν	CT	Ν	*	Low
mixed-methods																								
thesis																								
Whiteside and	Y	Y	Y	Y	Y			CT	Y	Ν	Y	Y						Ν	Y	Y	Y	Ν	***	Moderate
Ruckert, ⁴⁶ 2020;																								
mixed-methods																								
evaluation																								

Y (Yes), N (No), CT (Can't tell)